Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
Patent 5736577 Issued on April 7, 1998. Estimated Expiration Date: June 28, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/617, R contains benzene ring424/449, Transdermal or percutaneous424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/464, Tablets, lozenges, or pills514/540Nitrogen in Y moiety
A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its R enantiomer. Pharmaceutical compositions comprising (S)-oxybutynin, or a pharmaceutically acceptable salt thereof, substantially free of its R enantiomer, and a pharmaceutically acceptable carrier are also disclosed.
Other References
Lish et al. "Oxybutynin--A Musculotropic Antispasmodic Drug . . ." Arch. int. Pharmacodyn. 156, 456-488 (1965)
Hock "Clinical Evaluation of Oxybutynin Chloride" Current Therapeutic Research 9, 437-440 (1967)
Fredericks et al. "A Study of the Anticholinergic and Antispasmodic Activity of Oxybutynin . . ." Investigative Urology 12, 317-319 (1975)
Nilvebrant et al. "Dicyclomine, Benzhexol and Oxybutynine Distinguish . . ." Europ. J. Pharmacol. 123, 133-143 (1986)
Tonini et al. "Depressant Action of oxybutynin on the contractility . . ." J. Pharm. Pharmacol. 39, 103-107 (1986)
Kachur et al. "R and S Enantiomers of Oxybutynin: Pharmacological Effects . . ." J. Pharm. Exper. Ther. 247, 867-872 (1988)
Noronha-Blob et al. "Muscarinic Receptors: Relationships Among Phosphoinositude . . ." J. Pharm Exper. Ther. 249, 843-851 (1989)
Noronha-Blob et al. "The Anticholinergic Activity of Agents Indicated for Urinary . . ." J. Pharm. Exper. Ther. 251, 586-593 (1989)
Peterson et al. "In Vivo Crystometrogram Studies in Urethane-Anesthetized and Conscious Guinea Pigs" J. Pharm. Methods 21, 231-241 (1989)
Guarneri et al. "Effects of Oxybutynin, Terodiline, and Nifedipine . . ." Pharm. Research 24, 263-272 (1991)
Noronha-Blob et al. "Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization . . ." J. Pharm. Exp. Ther. 256, 562-567 (1990)
Lowe et al. "Effect of extracellular Ca2+ on cholinergic, KCl and phorbol ester-mediated . . ." Eur. J. Pharm. 195, 273-279 (1991)
Massad et al. "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride" J. Urology 148, 595-597 (1992)
Angelico et al. "In Vivo Effects of Different Antispasmodic Drugs on the Rat Bladder Contractions" J. Pharm. Methods 27, 33-39 (1992)
Guarneri et al. "Effects of Drugs Used in the Therapy of Detrusor Hyperactivity . . ." Pharm. Research 27, 173-187 (1993)
Lindeke et al. "Metabolism of Oxybutynin: establishment of desethyloxybutynin and Oxybutynin N-Oxide formation in Rat Liver Preparations using Deuterium Substitution and Gas Chromatographic Mass Spectrometric Analysis" Biomedical Mass Spectrometry, vol. 8, No. 10, 506-513 (1981)
Kasama et al. "Preparation of Substituted Glycolic acid 4-alkyl-amino-2-butynyl Esters as Antispasmodics and for Regulation of Urination" Chemical Abstracts, vol. 113:23118k, 586 (1990
June 28, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
